章程修正案 根据《中华人民共和国公司法》（以下简称《公司法》）的相关规定，结合 青岛国恩科技股份有限公司（以下简称"公司"）实际情况，公司将不再设置监 事会，监事会的职权由董事会审计委员会行使，公司《监事会议事规则》等监事 会相关制度相应废止，同时根据《公司法》《上市公司章程指引》等相关规定对 《青岛国恩科技股份有限公司章程》（以下简称《公司章程》）中相关条款亦作 出相应修订，并提请股东大会授权公司管理层全权办理相关工商备案登记事宜。 除"股东大会"修改为"股东会"、"或"修改为"或者"外，其他修订内容如 下： | 修订前 | 修订后 | | --- | --- | | 第一条 为维护公司、股东和债权人的合法 | 第一条 为维护公司、股东、职工和债权人的 | | 权益，规范公司的组织和行为，根据《中华人民 | 合法权益，规范公司的组织和行为，根据《中华 | | 共和国公司法》（以下简称"《公司法》"）、 | 人民共和国公司法》（以下简称"《公司法》"）、 | | 《中华人民共和国证券法》（以下简称"《证券 | 《中华人民共和国证券法》（以下简称"《证券 | | 法》"）和其他有关规定，制订本章程。 | 法》" ...

青岛国恩科技股份有限公司 2024 年度监事会工作报告 2024 年度，青岛国恩科技股份有限公司（以下简称"公司"）监事会全体成 员严格按照《中华人民共和国公司法》（以下简称《公司法》）《中华人民共和 国证券法》（以下简称《证券法》）《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及《公司章程》《监事会议事规则》等相关规 定和要求，本着维护公司利益和中小股东权益的原则，依法独立行使职权，全力 保障股东、公司和员工的合法权益。监事会对公司生产经营活动、重大事项、财 务状况以及董事、高级管理人员履行职责情况进行了监督，促进了公司规范运作。 现将监事会在 2024 年度的主要工作报告如下： 一、监事会日常工作情况 公司监事会在 2024 年度共召开了 5 次会议，具体情况如下： 1、第五届监事会第五次会议 2024 年 3 月 8 日，公司召开第五届监事会第五次会议，公司全体监事出席 了本次会议，会议审议通过了《关于回购公司股份方案的议案》。 2、第五届监事会第六次会议 2024 年 4 月 24 日，公司召开第五届监事会第六次会议，公司全体监事出席 了本次会议，会议审议通过了以下议案： （ ...

1、会计师事务所基本情况 名称：信永中和会计师事务所（特殊普通合伙） 青岛国恩科技股份有限公司 2024 年度会计师事务所履职情况评估报告 及董事会审计委员会履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《国有企业、上 市公司选聘会计师事务所管理办法》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范运作》及《公司章程》《董事会审计委员会工作细则》 等规定和要求，青岛国恩科技股份有限公司（以下简称"公司"或"本公司"） 第五届董事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事 会对会计师事务所 2024 年度履职情况评估及审计委员会履行监督职责的情况报 告如下： 一、2024 年年审会计师事务所的基本情况 成立日期：2012 年 3 月 2 日 组织形式：特殊普通合伙企业 注册地址：北京市东城区朝阳门北大街 8 号富华大厦 A 座 8 层 首席合伙人：谭小青先生 信永中和会计师事务所（特殊普通合伙）（以下简称"信永中和"）为多家 上市公司提供年报审计服务，涉及的主要行业包括制造业，信息传输、软件和信 息技术服务业，交通运输、仓储和邮政业，电力、热力、燃 ...

股票代码：002768 股票简称：国恩股份 公告编号：2025-015 青岛国恩科技股份有限公司 关于 2025 年度公司及子公司向金融机构申请授信额度并接 受关联方担保的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 青岛国恩科技股份有限公司（以下简称"国恩股份"或"公司"）于 2025 年 4 月 24 日召开的第五届董事会第十一次会议审议通过了《关于 2025 年度公 司及子公司向金融机构申请授信额度的议案》《关于接受关联方担保的议案》， 召开的第五届监事会第十次会议审议通过了《关于接受关联方担保的议案》， 现将有关事项公告如下： 一、向金融机构申请授信额度 根据公司及子公司经营发展的资金需求，2025 年公司及子公司拟向银行等 金融机构申请授信总额不超过人民币 300 亿元。公司及子公司在各金融机构办 理业务包括但不限于贷款、信用证、承兑汇票、保函及贸易融资等业务。授信 额度最终以金融机构实际审批金额为准，在授权期限内，授信额度可循环使用。 在授信总额范围内，公司可根据业务需要在不同金融机构间相互调剂。授权公 司总经理行使该项业务决策权并由财务负 ...

股票代码：002768 股票简称：国恩股份 公告编号：2025-020 青岛国恩科技股份有限公司 关于召开 2024 年度股东大会的通知 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 青岛国恩科技股份有限公司（以下简称"公司"）于 2025 年 4 月 24 日召 开了公司第五届董事会第十一次会议，会议审议通过了《关于召开 2024 年度股 东大会的议案》，董事会决议于 2025 年 6 月 6 日（星期五）召开公司 2024 年 度股东大会。现将本次会议的有关事项通知如下： 一、召开会议的基本情况 1、股东大会届次：2024 年度股东大会 2、股东大会的召集人：青岛国恩科技股份有限公司董事会 3、会议召开的合法、合规性：公司第五届董事会第十一次会议决定召开本 次股东大会。本次股东大会的召集、召开符合有关法律、行政法规、部门规章、 规范性文件、深圳证券交易所业务规则和《公司章程》等的规定。 4、会议召开的日期、时间： （1）现场会议召开时间：2025 年 6 月 6 日（星期五）下午 14:00。 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的 ...

股票代码：002768 股票简称：国恩股份 公告编号：2025-008 青岛国恩科技股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 2024 年度，公司监事会严格按照《公司法》《中华人民共和国证券法》等 法律法规、部门规章、规范性文件及《公司章程》《监事会议事规则》等规定， 从切实维护公司利益和全体股东的权益特别是广大中小股东权益出发，认真履行 监督职责。具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn） 上的《2024 年度监事会工作报告》。 表决结果：同意 3 票，反对 0 票，弃权 0 票。本议案获得表决通过。 本议案尚需提交公司 2024 年度股东大会审议。 2、审议通过《<2024 年年度报告>全文及摘要》 经审核，监事会认为董事会编制和审核公司《2024 年年度报告》全文及摘 要的程序符合法律、行政法规和中国证监会的规定，报告内容真实、准确、完整 地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者重大遗漏。具 体内容详见公司同日披露于巨潮资讯网（http:/ ...

股票代码：002768 股票简称：国恩股份 公告编号：2025-007 青岛国恩科技股份有限公司 第五届董事会第十一次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 青岛国恩科技股份有限公司（以下简称"公司"或"国恩股份"）第五届董 事会第十一次会议于 2025 年 4 月 24 日下午 14:00 在青岛市城阳区棘洪滩街道青 大工业园 2 号路公司办公楼四楼会议室召开。本次会议由公司董事长王爱国先生 召集并主持，会议通知于 2025 年 4 月 14 日以专人送达、电子邮件、电话等形式 发出。本次会议采取现场表决的方式召开，应参加本次会议表决的董事 7 人，实 际参加本次会议表决的董事为 7 人，公司监事及高级管理人员列席了本次会议。 本次会议的召集、召开和表决程序符合《中华人民共和国公司法》（以下简称《公 司法》）和《青岛国恩科技股份有限公司章程》（以下简称《公司章程》）的有 关规定，合法有效。 二、董事会会议审议情况 1、审议通过《2024 年度总经理工作报告》 表决结果：同意 7 票，反对 0 票，弃权 0 票。本 ...

股票代码：002768 股票简称：国恩股份 公告编号：2025-011 青岛国恩科技股份有限公司 关于 2024 年度利润分配预案的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 27,125 万股剔除回购专用证券账户中已回购股份 625 万股后的股本 26,500 万股 测算，预计 2024 年度派发现金红利 74,200,000.00 元。公司 2024 年度派发现金 红利和股份回购金额合计为 204,491,303.33 元，占公司 2024 年度归属于上市公 司股东的净利润的 30.23%。 三、现金分红方案的具体情况 1、公司 2024 年度利润分配方案不触及其他风险警示情形，最近三年现金 分红方案如下： | | | | 单位：元 | | --- | --- | --- | --- | | 项目 | 年度 2024 | 年度 2023 | 年度 2022 | | 现金分红总额 | 74,200,000.00 | 48,346,200.00 | 67,812,500.00 | | 回购注销总额 | 0.00 | 0.00 | 0.00 | | 归 ...

Financial Performance - The company's operating revenue for 2024 reached ¥19.22 billion, an increase of 10.21% compared to ¥17.44 billion in 2023[17]. - Net profit attributable to shareholders for 2024 was ¥676.38 million, reflecting a significant growth of 45.18% from ¥465.89 million in 2023[17]. - The basic earnings per share for 2024 increased to ¥2.52, up 46.51% from ¥1.72 in 2023[17]. - The total assets at the end of 2024 amounted to ¥18.35 billion, representing a 21.91% increase from ¥15.05 billion at the end of 2023[17]. - The net cash flow from operating activities for 2024 was ¥552.86 million, a rise of 13.26% compared to ¥488.11 million in 2023[17]. - The company reported a weighted average return on equity of 14.35% for 2024, up from 10.92% in 2023[17]. - The net profit after deducting non-recurring gains for 2024 was ¥530.66 million, which is a 14.71% increase from ¥462.61 million in 2023[17]. - The company recorded a total of ¥145.72 million in non-recurring gains for 2024, compared to ¥3.28 million in 2023[24]. Dividend and Shareholder Engagement - The company plans to distribute a cash dividend of 2.80 RMB per 10 shares (including tax) to all shareholders, with no bonus shares issued[4]. - The financial report confirms that all board members attended the meeting to review the annual report, ensuring accountability for the report's accuracy[4]. Market and Industry Outlook - The company plans to continue expanding its market presence and invest in new product development to drive future growth[26]. - The global chemical new materials market is expected to reach $480 billion by 2025, with a compound annual growth rate (CAGR) of 4.4% from 2019 to 2025[30]. - By 2025, China's consumption of chemical new materials is projected to reach 43 million tons, with a self-sufficiency rate of 85%[29]. - The pharmaceutical industry is expected to maintain an average annual growth rate of over 8% during the 14th Five-Year Plan period, with the added value of the industry increasing to 5% of total industrial output[32]. - The retail scale of China's nutrition and health food market exceeded $37 billion in 2023, with a CAGR of 7.0% over the past three years, projected to reach $44.2 billion by 2026[32]. Product Development and Innovation - The company is expanding its product applications into the medical field with the introduction of plasma gelatin, which is used in various medical applications[33]. - The company is actively investing in projects to produce 1 million tons of polystyrene (PS) annually, enhancing its competitive edge through economies of scale[35]. - The company has established a 200,000 tons/year styrene and 80,000 tons/year propylene oxide co-production facility, significantly improving raw material utilization and reducing carbon emissions[36]. - The company has an annual production capacity of 13,500 tons for gelatin and 39 billion capsules, with plans to expand capsule production to nearly 70 billion units, positioning itself as a leading producer in China[44]. - The company focuses on organic polymer modified materials, with applications in various industries including home appliances, automotive, and new energy sectors[39]. - The company has developed a three-tier value enhancement system from basic modification to high-end specialty materials, covering multiple industries and establishing long-term partnerships with major brands[40]. - The company aims to explore new business growth areas in lightweight materials for low-altitude eVTOL structures and smart wearable technologies[42]. Research and Development - The company has 300 ongoing technology innovation projects, ensuring sustainable development and leading domestic standards for modified materials[49]. - The company holds 47 invention patents and 162 utility model patents, demonstrating strong R&D capabilities in organic polymer materials[49]. - Research and development expenses increased by 4.42% to ¥591,283,695.30, indicating a continued focus on innovation[92]. - The number of R&D personnel increased by 33.81% to 752, with a notable rise in the proportion of personnel holding bachelor's degrees to 41.5%[98]. Environmental and Regulatory Compliance - The company is actively pursuing environmental management certifications, with multiple ISO certifications valid until 2027, reflecting its commitment to sustainability[52]. - The company has established a three-level safety production standardization enterprise certification, enhancing its operational safety protocols[52]. - The company is developing environmentally friendly and recyclable EPS products, achieving batch production and relevant certifications[61]. Strategic Partnerships and Acquisitions - The company completed the acquisition of 99.99% equity in Hong Kong Petrochemical, which has an annual production capacity of 250,000 tons of high-performance polystyrene[61]. - The company invested 240 million CNY to acquire a 67% stake in Guoen Chemical (Dongming), focusing on fine chemicals and new materials[62]. - The company has formed long-term strategic partnerships with leading enterprises such as Qilu Pharmaceutical and China National Pharmaceutical Group[74]. Corporate Governance and Management - The company held 1 annual general meeting and 5 board meetings during the reporting period, ensuring compliance with relevant laws and regulations[162]. - The company maintains complete independence in business operations, assets, personnel, and financial matters from its controlling shareholders[163]. - The company has established an independent financial accounting system and has independent bank accounts, ensuring no shared accounts with shareholders[165]. - The company has a comprehensive labor management system, ensuring all employees are independently employed and compensated by the company[163]. Future Outlook and Growth Strategies - The company is focused on expanding its market presence and enhancing its product offerings through strategic leadership[171]. - The company is actively pursuing new strategies for growth and market expansion in the coming years[171]. - The company is committed to enhancing the performance of its products through the development of new materials and production processes, particularly in the electric vehicle and charging station sectors[130].

Financial Performance - The company's revenue for Q1 2025 was ¥4,412,095,075.38, a decrease of 0.23% compared to ¥4,422,476,696.87 in the same period last year[5]. - Net profit attributable to shareholders was ¥111,050,160.99, down 9.79% from ¥123,108,552.29 year-on-year[5]. - The net profit excluding non-recurring gains and losses was ¥102,439,424.82, reflecting a decline of 16.78% compared to ¥123,092,034.96 in the previous year[5]. - Total operating revenue for the current period is CNY 4,412,095,075.38, a slight decrease of 0.23% compared to CNY 4,422,476,696.87 in the previous period[23]. - Net profit for the current period is CNY 113,725,169.20, down 17.0% from CNY 136,972,309.38 in the previous period[24]. - Earnings per share (EPS) for the current period is CNY 0.42, compared to CNY 0.45 in the previous period[25]. Cash Flow and Assets - Operating cash flow increased by 11.32% to ¥185,975,973.87 from ¥167,060,694.59 in the same period last year[5]. - Total cash inflow from investment activities is ¥941,572,747.68, significantly higher than ¥33,225,971.53 in the previous period[27]. - Net cash flow from financing activities is ¥434,965,470.21, up from ¥386,271,821.45 in the previous period, reflecting a growth of approximately 12.5%[27]. - The net increase in cash and cash equivalents for the current period is ¥537,471,820.55, compared to ¥517,638,650.36 in the previous period, indicating a growth of about 3.2%[27]. - The ending balance of cash and cash equivalents is ¥2,552,235,355.85, up from ¥2,262,430,044.04 in the previous period, representing an increase of approximately 12.8%[27]. - As of March 31, 2025, the company's total current assets reached RMB 11.62 billion, an increase from RMB 11.01 billion at the beginning of the period, reflecting a growth of approximately 5.54%[19]. - Total assets at the end of the reporting period were ¥18,971,169,046.25, up 3.38% from ¥18,351,446,492.55 at the end of the previous year[5]. Liabilities and Equity - Total liabilities rose to CNY 11,866,462,003.45, compared to CNY 11,319,117,568.76 in the previous period[21]. - The company’s total equity increased to CNY 7,104,707,042.80, up from CNY 7,032,328,923.79 in the previous period[21]. Expenses - Total operating costs increased to CNY 4,313,637,856.90, up 0.77% from CNY 4,303,784,754.56 in the previous period[23]. - Tax and additional charges increased by 48.82% year-on-year, mainly due to the consolidation of subsidiaries[13]. - Management expenses rose by 34.12% compared to the previous year, also attributed to the inclusion of subsidiaries[13]. - Financial expenses increased by 56.42% year-on-year, driven by increased loans and the consolidation of subsidiaries[13]. - Cash paid for taxes increased to ¥72,698,651.18 from ¥29,424,867.56, indicating a growth of about 147%[26]. Shareholder Information - The company has completed a share repurchase of 6,250,000 shares, accounting for 2.30% of the current total share capital, with a total transaction amount of approximately RMB 130.27 million[17]. - The company plans to use repurchased shares for employee stock ownership plans or equity incentives, with a repurchase budget between RMB 100 million and RMB 200 million[16]. - The maximum repurchase price was adjusted to RMB 23.82 per share after the 2023 dividend distribution[16]. - The company’s major shareholder, Wang Aiguo, holds 46.45% of the shares, making him the controlling shareholder[14]. - The top ten shareholders collectively hold significant stakes, with the largest being Qingdao Century Star Hao Investment Co., Ltd. at 18 million shares[14]. - The company has not disclosed any participation in margin financing or securities lending by the top ten shareholders[14]. Inventory and Receivables - Accounts receivable rose to RMB 2.79 billion from RMB 2.75 billion, indicating an increase of approximately 1.32%[19]. - Inventory levels increased to RMB 3.65 billion from RMB 3.38 billion, showing a growth of around 8.06%[19].